Drugs / Humalog lispro
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03383822 | Sep 2015 → Jul 2017 | type 2 diabetes mellitus | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Humalog lispro | “The insulin (Humalog Lispro 100 IU/ml, Eli Lily, Canada) and placebo (diluent) will be transferred to a metered nasal device” NCT03383822 ↗ |
| Route | Intranasal | “Humalog lispro 40 IU intranasally” NCT03383822 ↗ |